» Articles » PMID: 20409326

Astrocytic Expression of Parkinson's Disease-related A53T Alpha-synuclein Causes Neurodegeneration in Mice

Overview
Journal Mol Brain
Publisher Biomed Central
Date 2010 Apr 23
PMID 20409326
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease (PD) is the most common movement disorder. While neuronal deposition of alpha-synuclein serves as a pathological hallmark of PD and Dementia with Lewy Bodies, alpha-synuclein-positive protein aggregates are also present in astrocytes. The pathological consequence of astrocytic accumulation of alpha-synuclein, however, is unclear.

Results: Here we show that PD-related A53T mutant alpha-synuclein, when selectively expressed in astrocytes, induced rapidly progressed paralysis in mice. Increasing accumulation of alpha-synuclein aggregates was found in presymptomatic and symptomatic mouse brains and correlated with the expansion of reactive astrogliosis. The normal function of astrocytes was compromised as evidenced by cerebral microhemorrhage and down-regulation of astrocytic glutamate transporters, which also led to increased inflammatory responses and microglial activation. Interestingly, the activation of microglia was mainly detected in the midbrain, brainstem and spinal cord, where a significant loss of dopaminergic and motor neurons was observed. Consistent with the activation of microglia, the expression level of cyclooxygenase 1 (COX-1) was significantly up-regulated in the brain of symptomatic mice and in cultured microglia treated with conditioned medium derived from astrocytes over-expressing A53T alpha-synuclein. Consequently, the suppression of COX-1 activities extended the survival of mutant mice, suggesting that excess inflammatory responses elicited by reactive astrocytes may contribute to the degeneration of neurons.

Conclusions: Our findings demonstrate a critical involvement of astrocytic alpha-synuclein in initiating the non-cell autonomous killing of neurons, suggesting the viability of reactive astrocytes and microglia as potential therapeutic targets for PD and other neurodegenerative diseases.

Citing Articles

Autophagy in brain tumors: molecular mechanisms, challenges, and therapeutic opportunities.

Zhang J, Zhang J, Yang C J Transl Med. 2025; 23(1):52.

PMID: 39806481 PMC: 11727735. DOI: 10.1186/s12967-024-06063-0.


Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson's model.

Weiss F, Hughes L, Fu Y, Bardy C, Halliday G, Dzamko N Transl Neurodegener. 2024; 13(1):62.

PMID: 39681872 PMC: 11648304. DOI: 10.1186/s40035-024-00448-3.


Dysregulation of protein degradation and alteration of secretome in α-synuclein-exposed astrocytes: implications for dopaminergic neuronal dysfunction.

Raj A, Banerjee R, Holla V, Kamble N, Yadav R, Pal P Cell Commun Signal. 2024; 22(1):574.

PMID: 39617881 PMC: 11610152. DOI: 10.1186/s12964-024-01928-9.


α-Synuclein pathology as a target in neurodegenerative diseases.

Park H, Kam T, Dawson V, Dawson T Nat Rev Neurol. 2024; 21(1):32-47.

PMID: 39609631 DOI: 10.1038/s41582-024-01043-w.


Neuroprotective Effect of Maresin-1 in Rotenone-Induced Parkinson's Disease in Rats: The Putative Role of the JAK/STAT Pathway.

Khodir S, Sweed E, Faried M, Abo Elkhair D, Khalil M, Afifi K Neurochem Res. 2024; 50(1):30.

PMID: 39576344 PMC: 11584474. DOI: 10.1007/s11064-024-04282-x.


References
1.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

2.
Lee M, Stirling W, Xu Y, Xu X, Qui D, Mandir A . Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002; 99(13):8968-73. PMC: 124407. DOI: 10.1073/pnas.132197599. View

3.
Spillantini M, Goedert M . The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2001; 920:16-27. DOI: 10.1111/j.1749-6632.2000.tb06900.x. View

4.
Narhi L, Wood S, Steavenson S, Jiang Y, Wu G, Anafi D . Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999; 274(14):9843-6. DOI: 10.1074/jbc.274.14.9843. View

5.
Li W, West N, Colla E, Pletnikova O, Troncoso J, Marsh L . Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A. 2005; 102(6):2162-7. PMC: 548541. DOI: 10.1073/pnas.0406976102. View